Morgan Stanley’s Summit Therapeutics SMMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $21.1M | Sell |
1,450,019
-200,572
| -12% | -$3.56M | ﹤0.01% | 3044 |
|
|
2026
Q1 | $31.3M | Buy |
1,650,591
+724,012
| +78% | +$11.7M | ﹤0.01% | 2541 |
|
|
2025
Q4 | $16.2M | Sell |
926,579
-1,000,249
| -52% | -$18.8M | ﹤0.01% | 3129 |
|
|
2025
Q3 | $39.8M | Buy |
1,926,828
+1,284,827
| +200% | +$31.2M | ﹤0.01% | 2208 |
|
|
2025
Q2 | $13.7M | Buy |
642,001
+163,875
| +34% | +$3.74M | ﹤0.01% | 3153 |
|
|
2025
Q1 | $9.22M | Sell |
478,126
-82,864
| -15% | -$1.66M | ﹤0.01% | 3410 |
|
|
2024
Q4 | $10M | Sell |
560,990
-16,308
| -3% | -$316K | ﹤0.01% | 3413 |
|
|
2024
Q3 | $12.6M | Buy |
577,298
+240,181
| +71% | +$3.36M | ﹤0.01% | 3245 |
|
|
2024
Q2 | $2.63M | Sell |
337,117
-355,424
| -51% | -$1.92M | ﹤0.01% | 4378 |
|
|
2024
Q1 | $2.87M | Sell |
692,541
-11,731
| -2% | -$46.6K | ﹤0.01% | 4345 |
|
|
2023
Q4 | $1.84M | Buy |
704,272
+148,936
| +27% | +$306K | ﹤0.01% | 4569 |
|
|
2023
Q3 | $1.04M | Sell |
555,336
-36,650
| -6% | -$69.9K | ﹤0.01% | 4777 |
|
|
2023
Q2 | $1.49M | Sell |
591,986
-177,785
| -23% | -$324K | ﹤0.01% | 4606 |
|
|
2023
Q1 | $1.35M | Buy |
769,771
+550,834
| +252% | +$1.5M | ﹤0.01% | 4692 |
|
|
2022
Q4 | $930K | Sell |
218,937
-132,400
| -38% | -$241K | ﹤0.01% | 4911 |
|
|
2022
Q3 | $418K | Buy |
351,337
+142,144
| +68% | +$161K | ﹤0.01% | 5348 |
|
|
2022
Q2 | $209K | Sell |
209,193
-118,386
| -36% | -$166K | ﹤0.01% | 5874 |
|
|
2022
Q1 | $803K | Sell |
327,579
-30,605
| -9% | -$77.1K | ﹤0.01% | 5125 |
|
|
2021
Q4 | $963K | Buy |
358,184
+80,238
| +29% | +$386K | ﹤0.01% | 5099 |
|
|
2021
Q3 | $1.39M | Buy |
277,946
+60,409
| +28% | +$433K | ﹤0.01% | 4836 |
|
|
2021
Q2 | $1.62M | Buy |
217,537
+2,353
| +1% | +$15.4K | ﹤0.01% | 4792 |
|
|
2021
Q1 | $1.26M | Sell |
215,184
-38,923
| -15% | -$251K | ﹤0.01% | 4579 |
|
|
2020
Q4 | $1.19M | Buy |
254,107
+44,056
| +21% | +$187K | ﹤0.01% | 4565 |
|
|
2020
Q3 | $723K | Buy |
210,051
+90,481
| +76% | +$313K | ﹤0.01% | 4432 |
|
|
2020
Q2 | $355K | Sell |
119,570
-76,049
| -39% | -$262K | ﹤0.01% | 4782 |
|
|
2020
Q1 | $464K | Sell |
195,619
-38,159
| -16% | -$65.6K | ﹤0.01% | 4422 |
|
|
2019
Q4 | $374K | Buy |
233,778
+5,818
| +3% | +$9.35K | ﹤0.01% | 5095 |
|
|
2019
Q3 | $408K | Sell |
227,960
-16,241
| -7% | -$22K | ﹤0.01% | 4783 |
|
|
2019
Q2 | $309K | Buy |
244,201
+16,245
| +7% | +$27.2K | ﹤0.01% | 4833 |
|
|
2019
Q1 | $417K | Buy |
227,956
+44
| +0% | +$72 | ﹤0.01% | 4661 |
|
|
2018
Q4 | $262K | Sell |
227,912
-295
| -0.1% | -$459 | ﹤0.01% | 5173 |
|
|
2018
Q3 | $507K | Sell |
228,207
-25
| -0% | -$58 | ﹤0.01% | 4990 |
|
|
2018
Q2 | $559K | Sell |
228,232
-910
| -0.4% | -$11.7K | ﹤0.01% | 5025 |
|
|
2018
Q1 | $2.96M | Buy |
229,142
+160,103
| +232% | +$2M | ﹤0.01% | 3615 |
|
|
2017
Q4 | $765K | Buy |
+69,039
| New | +$770K | ﹤0.01% | 4724 |
|
|
2017
Q2 | – | Sell |
-6,721
| Closed | -$89K | – | 6649 |
|
|
2017
Q1 | $89K | Buy |
6,721
+2,721
| +68% | +$31.5K | ﹤0.01% | 5642 |
|
|
2016
Q4 | $34K | Buy |
4,000
+3,750
| +1,500% | +$40K | ﹤0.01% | 5851 |
|
|
2016
Q3 | $2K | Buy |
+250
| New | +$1.8K | ﹤0.01% | 6371 |
|
|
2016
Q2 | – | Sell |
-6
| Closed | – | – | 6643 |
|
|
2016
Q1 | $0 | Sell |
6
-1
| -14% | -$8 | ﹤0.01% | 6703 |
|
|
2015
Q4 | $0 | Sell |
7
-2
| -22% | -$21 | ﹤0.01% | 6785 |
|
|
2015
Q3 | $0 | Buy |
9
+1
| +13% | +$12 | ﹤0.01% | 6711 |
|
|
2015
Q2 | $0 | Buy |
+8
| New | +$91 | ﹤0.01% | 6741 |
|
Other funds holding SMMT
BBA
Morgan Stanley's SMMT Position: Q2 2026 in Review
Morgan Stanley reduced its Summit Therapeutics (SMMT) stake by 12% in Q2 2026, selling an estimated $3.56M and leaving 1,450,019 shares worth $21.1M. The position accounts for ﹤0.01% of the portfolio, ranked #3044.
Morgan Stanley first reported a position in SMMT in Q2 2015 and has held it in 42 quarters since. The position peaked at $39.8M in Q3 2025. 243 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.
- Morgan Stanley held 1,450,019 shares of Summit Therapeutics worth $21.1M as of Q2 2026.
- Morgan Stanley sold 200,572 Summit Therapeutics shares in Q2 2026, an estimated $3.56M.
- Summit Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #3044 holding.
- Morgan Stanley first reported a position in Summit Therapeutics in Q2 2015 and has held it in 42 quarters since.
- Morgan Stanley's Summit Therapeutics position peaked at $39.8M in Q3 2025.
- 243 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.